1. miRNAs can increase the efficiency of ex vivo platelet generation

   • Stephan Emmrich
   • Kerstin Henke
   • Jan-Henning Klusmann

   Original Article 05 July 2012 Pages: 1673 - 1684

   

2. Platelet activation and platelet–leukocyte interaction in β-thalassemia/hemoglobin E patients with marked nucleated erythrocytosis

   • Rassamon Keawvichit
   • Ladawan Khowawisetsut
   • Kovit Pattanapanyasat

   Original Article 31 July 2012 Pages: 1685 - 1694

   

3. Molecular mechanisms of a novel β-thalassaemia mutation due to the duplication of tetranucleotide ‘AGCT’ at the junction IVS-II/exon 3

   • Gennaro Musollino
   • Gabriella Mastrolonardo
   • Giuseppina Lacerra

   Original Article 24 July 2012 Pages: 1695 - 1701

   

4. FLT3 and NPM1 mutations in a cohort of AML patients and detection of a novel mutation in tyrosine kinase domain of FLT3 gene from Western India

   • Kanjaksha Ghosh
   • Suchitra Swaminathan
   • Baburao Vundinti

   Original Article 26 June 2012 Pages: 1703 - 1712

5. Activating CBL mutations are associated with a distinct MDS/MPN phenotype

   • Juliana Schwaab
   • Thomas Ernst
   • Andreas Reiter

   Original Article 10 August 2012 Pages: 1713 - 1720

   

6. Treatment of gastrointestinal diffuse large B cell lymphoma in China: a 10-year retrospective study of 114 cases

   • Xiaoyang Li
   • Weina Shen
   • Zhixiang Shen

   Original Article 26 June 2012 Pages: 1721 - 1729

   

7. The comparison between CHOP and R-CHOP in primary gastric diffuse large B cell lymphoma

   • Byeong Seok Sohn
   • Sun-Mok Kim
   • Cheolwon Suh

   Original Article 03 July 2012 Pages: 1731 - 1739

   

8. Value of surveillance computed tomography in the follow-up of diffuse large B-cell and follicular lymphomas

   • Tung-Liang Lin
   • Ming-Chung Kuo
   • Shu-Chen Lu

   Original Article 23 June 2012 Pages: 1741 - 1745

   

9. Prognostic relevance of pretreatment quality of life in diffuse large B-cell lymphoma patients treated with rituximab-CHOP: Results from a prospective cohort study

   • Hyun Ae Jung
   • Silvia Park
   • Won Seog Kim

   Original Article 28 June 2012 Pages: 1747 - 1756

   

10. Study on effectiveness of gemcitabine, dexamethasone, and cisplatin (GDP) for relapsed or refractory AIDS-related non-Hodgkin's lymphoma

    • Dong Ta Zhong
    • Chun Mei Shi
    • Jian Gang Liang

    Original Article 13 July 2012 Pages: 1757 - 1763

    

11. Current treatment of mantle cell lymphoma: results of a national survey and consensus meeting

    • M. Witzens-Harig
    • G. Hess
    • M. Dreyling

    Original Article 29 August 2012 Pages: 1765 - 1772

    

12. Low incidence of thromboembolism in relapsed/refractory myeloma patients treated with thalidomide without thromboprophylaxis in Taiwan

    • Shang-Yin Wu
    • Yu-Min Yeh
    • Tsai-Yun Chen

    Original Article 17 June 2012 Pages: 1773 - 1778

    

13. (Bortezomib plus lenalidomide/thalidomide)- vs (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials

    • Anyou Wang
    • Qiaohong Duan
    • Zimin Sun

    Original Article 07 July 2012 Pages: 1779 - 1784

    

14. Radiotherapy for solitary plasmacytoma of bone and soft tissue

    • Yang-Gun Suh
    • Chang-Ok Suh
    • Jaeho Cho

    Original Article 30 June 2012 Pages: 1785 - 1793

    

15. The use of adjusted ideal body weight for overweight patients undergoing HPC mobilisation for autologous transplantation

    • C. Hicks
    • A. Trickett
    • S. Ramanathan

    Original Article 27 July 2012 Pages: 1795 - 1801

    

16. Phytohemagglutinin-activated human T cells induce lethal graft-versus-host disease in cyclophosphamide and anti-CD122 conditioned NOD/SCID mice

    • Yongxian Hu
    • Yanjun Gu
    • He Huang

    Original Article 15 June 2012 Pages: 1803 - 1812

    

17. ABL1 deletion without BCR/ABL1 rearrangement is originated from a large-sized 9q deletion

    • Jungwon Huh
    • Yeung Chul Mun
    • Wha Soon Chung

    Letter to the Editor 29 March 2012 Pages: 1813 - 1815

    

18. Primary mucosa-associated lymphoid tissue (MALT) lymphoma of the liver: clinical, molecular, and microbiological aspects

    • Barbara Kiesewetter
    • Leonhard Müllauer
    • Markus Raderer

    Letter to the Editor 04 April 2012 Pages: 1817 - 1818

19. Usefulness of double-balloon enteroscopy for evaluation of duodenal follicular lymphoma

    • Sho Hangai
    • Fumihiko Nakamura
    • Mineo Kurokawa

    Letter to the Editor 27 April 2012 Pages: 1819 - 1820

    

20. Primary intraocular lymphoma in a patient with systemic lupus erythematosus

    • Feng Jung S. H. Woei-A-Jin
    • Sabina Kersting
    • Jan Geert Bollemeijer

    Letter to the Editor Open access 03 May 2012 Pages: 1821 - 1822

    

21. Fasting glucose level reduction induced by imatinib in chronic myeloproliferative disease with TEL-PDGFRβ rearrangement and type 1 diabetes

    • Adriano Salaroli
    • Giuseppina Loglisci
    • Massimo Breccia

    Letter to the Editor 24 May 2012 Pages: 1823 - 1824

22. Philadelphia-negative acute promyelocytic leukemia in a patient with chronic myeloid leukemia in complete cytogenetic response after treatment with tyrosine kinase inhibitor

    • Kyoko Inokura
    • Yasushi Onishi
    • Hideo Harigae

    Letter to the Editor 29 April 2012 Pages: 1825 - 1826

23. Visceral leishmaniasis infection in a refractory multiple myeloma patient treated with bortezomib

    • Eugenio Piro
    • Mariagrazia Kropp
    • Stefano Molica

    Letter to the Editor 15 May 2012 Pages: 1827 - 1828

    

24. A novel frameshift mutation Gly239Serfs*8 in the PROC gene results in protein C deficiency in a Korean patient

    • Sang Hyuk Park
    • Seongsoo Jang
    • Yeon-Mok Oh

    Letter to the Editor 16 May 2012 Pages: 1829 - 1830

    

25. Deep vein thrombosis associated with factor V inhibitor followed by immune thrombocytopenia

    • Takakazu Higuchi
    • Takeshi Okamoto
    • Sadamu Okada

    Letter to the Editor 16 May 2012 Pages: 1831 - 1832